Page last updated: 2024-11-02

piracetam and Neuroleptic Malignant Syndrome

piracetam has been researched along with Neuroleptic Malignant Syndrome in 2 studies

Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.

Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Whyte, CJ1
Rosini, JM1
Verma, R1
Junewar, V1
Rathaur, BP1

Other Studies

2 other studies available for piracetam and Neuroleptic Malignant Syndrome

ArticleYear
Dantrolene for Treatment of Suspected Neuroleptic Malignant Syndrome.
    Journal of emergency nursing, 2018, Volume: 44, Issue:2

    Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dantrolene; Diagnosis, D

2018
An atypical case of neuroleptic malignant syndrome precipitated by valproate.
    BMJ case reports, 2014, Mar-06, Volume: 2014

    Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Dopamine Agonists; Drug Ther

2014